Literature DB >> 18640717

PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines.

Mariana G García1, Laura D Alaniz, Rosalía I Cordo Russo, Elida Alvarez, Silvia E Hajos.   

Abstract

Upregulation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway has been described in some tumors related to multidrug resistance (MDR). The aim of this work was to analyze the relationship between PI3K/Akt, MDR and NF-kappaB in murine lymphoma cell lines resistant to vincristine (LBR-V160) and doxorubicin (LBR-D160) as well as in the sensitive line (LBR-). PI3K/Akt activity, analyzed by phosphatidylinositol trisphosphate production and phosphorylated Akt (p-Akt) expression, was higher in the resistant cell lines than in the sensitive one and inhibition with wortmannin or LY294002 improved apoptosis in the resistant cell lines. Vincristine but not doxorubicin increased p-Akt expression whereas co-treatment with PI3K inhibitors and vincristine increased apoptosis in the three cell lines. Wortmannin and LY294002 inhibited P-glycoprotein (Pgp) function and also increased NF-kappaB activity. We concluded that the PI3K/Akt pathway is involved in MDR in lymphoma cell lines and PI3K/Akt inhibition correlates down-regulation of NF-kappaB activity and inhibition Pgp function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640717     DOI: 10.1016/j.leukres.2008.06.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  27 in total

1.  Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy.

Authors:  Daniela Laura Papademetrio; Silvina Laura Lompardía; Tania Simunovich; Susana Costantino; Cintia Yamila Mihalez; Victoria Cavaliere; Élida Álvarez
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493

2.  7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells.

Authors:  Sheng-Fan Wang; Yueh-Ching Chou; Nirmal Mazumder; Fu-Jen Kao; Leslie D Nagy; F Peter Guengerich; Cheng Huang; Hsin-Chen Lee; Ping-Shan Lai; Yune-Fang Ueng
Journal:  Biochem Pharmacol       Date:  2013-06-19       Impact factor: 5.858

3.  PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.

Authors:  Feifei Wen; Shuang He; Chenbo Sun; Tangyue Li; Shuhua Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

4.  STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer.

Authors:  Dimitrios Iliopoulos; Savina A Jaeger; Heather A Hirsch; Martha L Bulyk; Kevin Struhl
Journal:  Mol Cell       Date:  2010-08-27       Impact factor: 17.970

5.  The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.

Authors:  Robert O'Connor; Melissa G Ooi; Justine Meiller; Jana Jakubikova; Steffen Klippel; Jake Delmore; Paul Richardson; Kenneth Anderson; Martin Clynes; Constantine S Mitsiades; Peter O'Gorman
Journal:  Cancer Chemother Pharmacol       Date:  2013-04-16       Impact factor: 3.333

6.  NFI-A disrupts myeloid cell differentiation and maturation in septic mice.

Authors:  Clara McClure; Ekram Ali; Dima Youssef; Zhi Q Yao; Charles E McCall; Mohamed El Gazzar
Journal:  J Leukoc Biol       Date:  2015-08-10       Impact factor: 4.962

7.  PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.

Authors:  Shuhua Wu; Feifei Wen; Yangyang Li; Xiangqian Gao; Shuang He; Mengyao Liu; Xiangzhi Zhang; Dong Tian
Journal:  Tumour Biol       Date:  2016-01-08

Review 8.  Stem-like cells and therapy resistance in squamous cell carcinomas.

Authors:  Nicole Facompre; Hiroshi Nakagawa; Meenhard Herlyn; Devraj Basu
Journal:  Adv Pharmacol       Date:  2012

9.  Low intensity ultrasound promotes the sensitivity of rat brain glioma to Doxorubicin by down-regulating the expressions of p-glucoprotein and multidrug resistance protein 1 in vitro and in vivo.

Authors:  Zhen Zhang; Ke Xu; Yonghua Bi; Guibo Yu; Siwei Wang; Xun Qi; Hongshan Zhong
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

10.  Non-Hodgkin Lymphoma Metabolism.

Authors:  Brian James Kirsch; Shu-Jyuan Chang; Michael James Betenbaugh; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.